|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||13.22 - 13.95|
|52 Week Range||6.51 - 37.99|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
WALTHAM, Mass., June 16, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company’s business development efforts as well as supporting corporate strategy initiatives.
WALTHAM, Mass., June 02, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:
WALTHAM, Mass., May 04, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.